Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 10/20 | 0.60 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6955527 | 1.00 | CASP1 (0.60) | CASP1CTRB1CTSLCTSSALDH1A1 | |
| SCHEMBL6156731 | 1.00 | CASP1 (0.60) | CASP1CTRB1CTSLCTSSALDH1A1 | |
| SCHEMBL14562401 | 0.93 | KLK1 (0.57) | CASP1CTRB1 | |
| SCHEMBL15654961 | 0.90 | CASP1 (0.51) | CASP1CTRB1 | |
| SCHEMBL1232637 | 0.90 | CASP1 (0.51) | CASP1CTRB1CTSLCTSSATM | |
| SCHEMBL9830798 | 0.90 | F2 (0.52) | CASP1CTSLCTSSATM | |
| SCHEMBL10885690 | 0.88 | CTRB1 (0.51) | CASP1CTRB1CTSLCTSSALDH1A1 | |
| SCHEMBL7285800 | 0.88 | ATM (0.55) | CASP1CTRB1CTSLCTSSALDH1A1 | |
| SCHEMBL10885697 | 0.88 | CTRB1 (0.51) | CASP1CTRB1CTSLCTSSALDH1A1 | |
| SCHEMBL14562429 | 0.88 | ATM (0.62) | CASP1CTSLCTSSALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| CN-114585628-B | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-06 | — | — | US | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-4013759-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585628-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-3186224-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-6191282-B1 | DERIVATIVES OF 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING IS USED AS ANTICARCINOGENIC AGENT AND ANTICOAGULANT | HOECHST MARION ROUSSEL (DE) | 2001-02-20 | — | — | US | disclosed |
| WO-2000069831-A1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-23 | — | — | WO | disclosed |
| EP-1021424-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5981492-A | ADMINISTERED TO THE PATIENT TO INHIBIT THROMBOCYTE AGGREGATION, THE METASTASIZATION OF CARCINOMA CELLS, THE BINDING OF OSTEOCLASTS TO THE BONE SURFACE, OR FOR THE TREATMENT OF THROMBOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| EP-0670310-B1 | Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants | LILLY CO ELI (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997048688-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5488037-A | ARGININE ALDEHYDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0671390-A2 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0670310-A1 | Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants | ELI LILLY AND COMPANY (US) | 1995-09-06 | — | — | EP | disclosed |
| US-5436229-A | Di- and tripeptides as anticoagulants | ELI LILLY AND COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CASP1 4318/4885CTRB1 381/4885CTSL 2337/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | CASP1 4733/4885CTRB1 3135/4885CTSL 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.